Lupin has launched topiramate extended-release capsules (25 mg, 50 mg, 100 mg, 200 mg) in the US after FDA ANDA approval. The capsules are bioequivalent to Trokendi XR and are indicated for partial-onset and generalised seizures, Lennox-Gastaut syndrome, and migraine prevention. The US market for the drug is estimated at $164 million annually.
